Scotia Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$79.9M Sell
86,840
-10,110
-10% -$10.2M 0.33% 59
2025
Q4
$104M Buy
96,950
+4,491
+5% +$4.29M 0.42% 43
2025
Q3
$70.5M Sell
92,459
-4,647
-5% -$3.46M 0.3% 61
2025
Q2
$75.7M Buy
97,106
+7,864
+9% +$6.11M 0.36% 53
2025
Q1
$73.7M Buy
89,242
+7,886
+10% +$6.56M 0.4% 50
2024
Q4
$62.8M Sell
81,356
-12,908
-14% -$10.7M 0.33% 53
2024
Q3
$83.5M Buy
94,264
+27,679
+42% +$24.9M 0.45% 48
2024
Q2
$60.3M Buy
66,585
+7,941
+14% +$6.35M 0.35% 55
2024
Q1
$45.6M Buy
58,644
+11,791
+25% +$8.39M 0.27% 63
2023
Q4
$27.3M Buy
46,853
+3,478
+8% +$2.03M 0.18% 86
2023
Q3
$23.3M Buy
43,375
+6,087
+16% +$3.14M 0.17% 89
2023
Q2
$17.5M Buy
37,288
+981
+3% +$411K 0.12% 110
2023
Q1
$12.5M Buy
36,307
+1,981
+6% +$668K 0.09% 135
2022
Q4
$12.6M Buy
34,326
+277
+0.8% +$98.2K 0.1% 133
2022
Q3
$11M Sell
34,049
-13,166
-28% -$4.17M 0.09% 138
2022
Q2
$15.3M Buy
47,215
+2,399
+5% +$720K 0.11% 117
2022
Q1
$12.8M Buy
44,816
+2,505
+6% +$645K 0.08% 142
2021
Q4
$11.7M Sell
42,311
-2,780
-6% -$705K 0.08% 152
2021
Q3
$10.4M Buy
45,091
+16,849
+60% +$4.16M 0.08% 149
2021
Q2
$6.48M Buy
28,242
+548
+2% +$110K 0.05% 216
2021
Q1
$5.17M Buy
27,694
+201
+0.7% +$39.3K 0.04% 229
2020
Q4
$4.64M Sell
27,493
-746
-3% -$111K 0.04% 223
2020
Q3
$4.18M Sell
28,239
-6,949
-20% -$1.08M 0.05% 210
2020
Q2
$5.78M Buy
35,188
+10,240
+41% +$1.57M 0.08% 144
2020
Q1
$3.46M Sell
24,948
-9,404
-27% -$1.29M 0.05% 189
2019
Q4
$4.51M Sell
34,352
-1,797
-5% -$208K 0.05% 185
2019
Q3
$4.04M Sell
36,149
-207
-0.6% -$23K 0.05% 190
2019
Q2
$4.03M Sell
36,356
-1,579
-4% -$186K 0.05% 193
2019
Q1
$4.92M Sell
37,935
-31,846
-46% -$3.87M 0.06% 170
2018
Q4
$8.07M Buy
69,781
+15,221
+28% +$1.7M 0.12% 112
2018
Q3
$5.86M Sell
54,560
-39,350
-42% -$3.93M 0.07% 159
2018
Q2
$7.23M Buy
93,910
+1,116
+1% +$91.7K 0.1% 132
2018
Q1
$7.18M Sell
92,794
-32,524
-26% -$2.62M 0.1% 137
2017
Q4
$10.6M Buy
125,318
+17,465
+16% +$1.49M 0.14% 104
2017
Q3
$9.22M Buy
107,853
+8,473
+9% +$695K 0.13% 111
2017
Q2
$8.18M Buy
99,380
+17,296
+21% +$1.41M 0.14% 108
2017
Q1
$6.91M Buy
82,084
+12,822
+19% +$1.03M 0.12% 121
2016
Q4
$5.1M Buy
69,262
+30,401
+78% +$2.26M 0.08% 164
2016
Q3
$3.12M Buy
38,861
+4,843
+14% +$388K 0.06% 222
2016
Q2
$2.69M Buy
34,018
+1,676
+5% +$126K 0.05% 223
2016
Q1
$2.33M Buy
32,342
+5,449
+20% +$412K 0.05% 217
2015
Q4
$2.22M Hold
26,893
0.05% 246
2015
Q3
$2.25M Buy
26,893
+2,161
+9% +$182K 0.05% 235
2015
Q2
$2.06M Sell
24,732
-5,757
-19% -$439K 0.04% 275
2015
Q1
$2.22M Sell
30,489
-1,704
-5% -$121K 0.06% 208
2014
Q4
$2.22M Sell
32,193
-40,683
-56% -$2.75M 0.06% 199
2014
Q3
$4.72M Buy
72,876
+16,489
+29% +$1.04M 0.1% 124
2014
Q2
$3.51M Buy
56,387
+15,478
+38% +$923K 0.08% 149
2014
Q1
$2.41M Sell
40,909
-11,520
-22% -$643K 0.05% 180
2013
Q4
$2.67M Buy
52,429
+21,297
+68% +$1.07M 0.06% 168
2013
Q3
$1.57M Buy
31,132
+22,696
+269% +$1.19M 0.04% 204
2013
Q2
$414K Buy
+8,436
New +$459K 0.02% 319

Other funds holding LLY

Scotia Capital's LLY Position: Q1 2026 in Review

Scotia Capital reduced its Eli Lilly (LLY) stake by 10% in Q1 2026, selling an estimated $10.2M and leaving 86,840 shares worth $79.9M. The position accounts for 0.33% of the portfolio, ranked #59.

Scotia Capital first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $104M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Scotia Capital held 86,840 shares of Eli Lilly worth $79.9M as of Q1 2026.
  • Scotia Capital sold 10,110 Eli Lilly shares in Q1 2026, an estimated $10.2M.
  • Eli Lilly made up 0.33% of Scotia Capital's portfolio in Q1 2026, its #59 holding.
  • Scotia Capital first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Scotia Capital's Eli Lilly position peaked at $104M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.